Adrenocortical carcinoma secondary prevention

	Adrenocortical carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Adrenocortical carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
MRI
CT
Ultrasound
Other Imaging Studies
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Radiation Therapy
Primary prevention
Secondary prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Study
Case #1
Adrenocortical carcinoma secondary prevention On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Adrenocortical carcinoma secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Adrenocortical carcinoma secondary prevention
CDC on Adrenocortical carcinoma secondary prevention
Adrenocortical carcinoma secondary prevention in the news
Blogs on Adrenocortical carcinoma secondary prevention
Hospitals Treating Adrenocortical carcinoma
Risk calculators and risk factors for Adrenocortical carcinoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years.

Surveillance should also include:
- Cross-sectional imaging of chest, abdomen, and pelvis
- The use of FDG-PET for lesions of an unclear nature
- Laboratory evaluation for steroid hormones
- Evaluation of side effects is also important in case of adjuvant mitotane therapy